a16z Bio + Health’s cover photo
a16z Bio + Health

a16z Bio + Health

Financial Services

Backing bold entrepreneurs who are engineering biology and reimagining healthcare.

About us

Backing bold entrepreneurs who are engineering biology and reimagining healthcare.

Website
https://a16z.com/bio/
Industry
Financial Services
Company size
201-500 employees
Headquarters
The Cloud

Updates

  • a16z Bio + Health reposted this

    Exactly two years ago today, Counsel Health was born from the simple realization that the world needs many more clinicians, and that safe, clinical AI could be the answer. Since then, we’ve cared for thousands of patients through leading enterprise partnerships, and we’ve strengthened our conviction that physician-supervised AI care models are the future of medicine. Fortunately, we’re not alone in this belief. Today, I’m proud to share that we’ve raised an oversubscribed $25M Series A, co-led by Andreessen Horowitz, and GV (Google Ventures), with participation from all existing investors (Asymmetric, Floodgate, Pear VC). This milestone is special for many reasons. First, we’re honored to have a16z’s continued support, just nine months after they led our Seed round. Over the past year, I’ve had the chance to work closely with Julie Yoo and Jay Rughani, and I’ve been struck by their intelligence, rigor, and tireless commitment to their founders, characteristics which have helped cement their reputation as amongst the best healthcare investors. We’re equally thrilled to welcome GV, specifically Krishna Yeshwant (co-lead of their Life Sciences practice) and David Reshef. The GV team represents some of the most thoughtful investors I’ve ever met — many are actively practicing physicians and PhD-level computer scientists — a combination that feels especially aligned to the Counsel ethos. This milestone also validates the importance we place on responsible AI development. Across the world, there’s a rising unease about what AI means for the future of work, truth, and human relevance. From day one, we’ve believed that clinical AI must be developed by physicians, not apart from them. That our mission can only be achieved by combining artificial and human intelligence, not by choosing between them. In fact, the cursive nature of Counsel's new brandmark pays homage to the physician signatures of the pre-internet era, a reminder that the human touch in medicine must never slip away. Alongside the fundraise, we’re also excited to announce that starting today, Counsel is available to the general public — you can sign up for your own account. Our leading medical AI is completely free to use, and you can add a real Counsel physician into any conversation within minutes, with a single click. We hope you’ll trust Counsel to become your home for health records, medical questions, and ongoing care. Finally, a heartfelt thank you to our enterprise partners and our mission-driven team. We are only at the beginning of what we can accomplish together.

  • a16z Bio + Health reposted this

    View profile for Jay Rughani

    Investment Partner at Andreessen Horowitz | Health + Bio

    What if you had the world's best doctor by your side for life? A doctor who is always available, extremely knowledgeable, and completely personalized to you. Right now, our healthcare system looks nothing like that vision. Today, over 100 million people in the U.S. don’t have a dedicated doctor, and even those who do often wait weeks to see them. Our healthcare system is designed to ration access to our scarcest resource – doctor time. And in a world where clinician capacity is scarce, people are forced to turn to Google or ChatGPT for answers. Consumers ultimately need clinical resolution: the prescription, the lab test, the specialist appointment, the follow-up, the ongoing guidance and encouragement to change their lifestyle. So what would healthcare abundance look like in the age of AI? It would look like Counsel Health. Counsel is a full-stack, AI native medical group that makes medical care abundant – unlimited guidance from real doctors, scaled by Counsel’s medical AI. This system embodies several qualities that everyone should expect from AI as a new site of care, which go far beyond the simplistic, early models of digital health that simply replicated offline visits on a computer screen: 1. Always available (and actionable): Care when you need it, not weeks later. By making doctors the true front door to care, Counsel prevents the typical swirl that occurs when we gate access to physicians. 2. Extremely knowledgeable: Medical knowledge doubles every few months. No human can keep up. Counsel’s AI spans the entire corpus of medical knowledge, across every discipline, and brings it straight to the point of care. 3. Completely personalized: Counsel’s AI remembers – it maintains context across every interaction, building a data flywheel for more personalization over time. As clinicians validate and reinforce the AI recommendations, Counsel steadily makes more of its interactions autonomous. Counsel is led by Muthu Alagappan, MD, who has lived at the intersection of AI, medicine, and healthtech for more than a decade. Previously a Stanford-trained physician, AI researcher, and chief medical officer at a high-growth healthtech company, he combines deep clinical expertise with a builder’s intuition for how to redesign care models in the age of AI. We led Counsel’s seed financing last year because of our conviction in this bold idea: that we can build a world in which everyone has their own doctor for life. In the months since, the company has made immense progress toward that future. That’s why we’re thrilled to double down on Counsel Health and co-lead their Series A, along with our friends at GV (Google Ventures). Counsel is redefining what it means to access healthcare: no longer scarce, but abundant. Andreessen Horowitz a16z Bio + Health Julie Yoo Sherman L. Rajko Radovanović Krishna Yeshwant David Reshef Asymmetric Rob Biederman Nancy Chou Floodgate Ann Miura-Ko Pear VC Mar Hershenson

  • Clinical trials can’t move forward without patients — and Alleviate Health is helping fix that. We’re thrilled to back Alleviate Health, which is transforming how research sites recruit patients with human-in-the-loop AI agents — combining automation with the empathy and precision clinical trials demand. Already live at 190+ sites across the U.S. and Canada, Alleviate is empowering research teams to engage patients faster, streamline operations, and get new treatments to market sooner. Congrats to founders Saathvik Boompelli and John Xu, and welcome to the a16z Bio + Health portfolio!

    View profile for Saathvik Boompelli

    Co-Founder @ Alleviate Health

    Excited to announce our $4.3M fundraising, led by Andreessen Horowitz with participation from Alt Capital and First Harmonic and the public launch of Alleviate Health. Alleviate empowers research sites’ best recruiters to connect with more patients by making their days 10x more efficient. Our SMS and Voice agents engage patients at scale, pass them to recruiters if they pre-qualify via a transferred or scheduled call, and automatically update any CTMS or CRM. We’re already working with 7 of the top 15 research site networks in the country with customers like Alcanza Clinical Research, CenExel, Centricity Research, M3 Wake Research, Eximia Research, and Profound Research along with many more unannounced partnerships. Our agents have been battle-tested across 500k+ patient interactions, 190+ sites, and 300+ unique trials. They yield the highest conversion rates of any solution on the market because they’ve been optimized across every possible patient population, indication, and workflow in the recruitment process. While we’re proud of the numbers, the feedback that’s taped to the wall in our office is from customers like Haley Mcsweeney, a patient recruiter from London, Ohio. Before Alleviate, Haley said she “could spend a whole day calling patients, and no one would pick up” and now she has “more than doubled” the number of patients she’s able to recruit at her site. Despite the constant noise around AI in this industry, it will never replace the human connection needed to successfully recruit patients for clinical trials. However, it can remove the drudgery of initial pre-screening, outbound calls, voicemails, and manual updating of systems that Haley has dealt with for years, making her ability to connect with patients an order of magnitude more effective (and enjoyable). If you’re a site looking to accelerate patient recruitment, we’d love to partner with you. Book a demo at https://lnkd.in/eBTxakVC. We're also hiring across all roles: email us at careers@alleviatehealth.care

  • 🎉 Congratulations to Cartography Biosciences on their $67M Series B, led by Pfizer Ventures with participation from an incredible group of new and existing investors. We’re proud to continue backing Cartography as they advance their differentiated oncology pipeline into the clinic—starting with their lead T-cell engager for colorectal cancer—and expand the next wave of programs from their ATLAS and SUMMIT platforms. An exciting milestone on the path to bringing new therapies to patients. 🚀

    View profile for Kevin Parker

    Co-Founder, CEO at Cartography Biosciences

    Proud to announce Cartography Biosciences’s Series B this morning! Back in 2020, Ansuman Satpathy, Howard Chang, and I started thinking about how to find the next generation of targets in oncology. We were fortunate that Jorge Conde a16z Bio + Health and Sara Choi Wing Venture Capital took a bet on us and the idea, and helped us launch off the ground, and 8VC led our Series A to help us continue to grow. Today, I’m thrilled to welcome Michael Baran from Pfizer Ventures to our board as the lead of our Series B, and Troy Wilson as the chairperson of our board as well. We’re fortunate to be working with them and for the support of all of our other investors and partners. I continue to believe in the need and opportunity of new targets to build new pipelines; that the best therapeutics will come from the best targets. Taking on new biology is a hard challenge, but it’s a challenge worth working on. I couldn’t ask for a better team of people within and around Cartography to be working on it with. https://lnkd.in/gWBiQtgp

  • What will it take to invest in the next era of healthcare? On September 29, Julie Yoo brings her perspective to center stage at #Sessions2025 — unpacking how political and regulatory changes are influencing capital strategies, risk, and opportunities in care delivery. Don’t miss this must-see discussion that sets the tone for the future of healthcare investment. Join Julie alongside industry leaders, Adam Boehler and Vijay Jun Patel for this must-see discussion that sets the tone for the future of healthcare investment. Sessions 2025 is produced by the @Nashville Health Care Council. https://lnkd.in/eQ7PsPng #Sessions2025  @NashvilleHealthCareCouncil.

    View organization page for Nashville Health Care Council

    11,084 followers

    First Sessions 2025 Panel Announcement! Get ready for a powerful conversation on Investing in a New Era of Healthcare — kicking off Monday, September 29. Join moderator Jed Brody, Managing Director and Head of Healthcare, Americas at Barclays Capital, alongside an elite panel of leaders: 🔹Adam Boehler, Founder & Managing Partner, Rubicon Founders 🔹 Vijay Jun Patel, Managing Partner, CVS Health Ventures 🔹Julie Yoo, General Partner, a16z In a healthcare landscape shaped by evolving CMS priorities and the “Make America Healthy Again” movement, this panel will dive deep into how political and regulatory shifts are reshaping deal flow, valuations, and risk tolerance. Discover new investment opportunities in key areas like primary care access, behavioral health, home-based care, and cost containment. Learn how capital strategies are evolving for investors and operators alike — and what to watch as we head toward a pivotal 2026. Don’t miss this must-see discussion that sets the tone for the future of healthcare investment. 🔗 Register now for Sessions 2025 and be part of the conversation! https://hubs.li/Q03C8jjC0 Thank you to our Sessions 2025 sponsors Sustaining: Acadia Healthcare, Ascension Saint Thomas, Community Health Systems, HCA Healthcare, Lifepoint Health® & Premise Health Premier: Barclays, Optum, Oracle Health Alliance: athenahealth, Bank of America, Polsinelli & Shearwater Health Vital Edge Sponsors: Alight Solutions, Bass, Berry & Sims, Bradley Arant Boult Cummings LLP, Epstein Becker & Green, P.C., Holland & Knight LLP Podcast Booth: Jefferies News Announcement Sponsor: MEDITECH Get Business Done Lounge Sponsor: Music City PrEP Clinic, Saviynt& TeamHealth Media Partner: Modern Healthcare Host City: Nashville Music City Center Digital Partner: EES Agency Partial sponsor list displayed. Additional 2025 sponsors coming soon.

    • No alternative text description for this image
  • AI is reshaping how care is delivered — not by replacing physicians, but by informing and supporting clinical decision-making. At the (#WMIF2025) World Medical Innovation Forum, Andreessen Horowitz Investing Partner Jay Rughani will join leading experts to discuss how computational approaches are transforming diagnostics — from leveraging imaging, genomics, EEGs, and radiology data to enabling earlier detection and more personalized care. Equally important, the conversation will focus what’s required to scale: - Regulatory clarity to ensure safety and trust - Reimbursement pathways to incentivize adoption - Workflow integration so AI enhances, not disrupts, clinical practice 📆 Tuesday, September 16, 2025 | 1:00 – 1:40 PM 🎤 Moderated by Danielle Bitterman with speakers including Andrew Beck, Jacob Donoghue, MD PhD, Connie Lehman and David Spetzler, we’re excited to be part of the dialogue on how AI can empower clinicians, improve outcomes, and enable a more personalized future of care.

  • AI isn’t just another tool in healthcare—it’s redefining the roles we play, the value we create, and the future we can build together. Next week at the 2025 Oliver Wyman Health Innovation Summit, Julie Yoo, General Partner at a16z Bio + Health, will take the stage to explore: What happens when AI becomes truly ubiquitous in healthcare—and how do we rethink the roles of patients, providers, and innovators in that new reality? Alongside industry leaders Mike Vennera and John Lester, Julie will be exchanging ideas on how AI will transform every corner of the ecosystem—from policy and practice to access and experience. Find out more > https://owy.mn/4mDQLnj #OWHIC

    • No alternative text description for this image
  • We’re inspired by the incredible work on display at #2025USCHA— and proud to see partners like Alchemy, NMAC, and Magic Johnson leading the way in reimagining equitable, high-quality access to HIV care. From advancing treatment and access to tackling stigma and shaping policy, their efforts remind us what’s possible when innovation and advocacy come together to support patients and communities.

    View organization page for Alchemy

    3,532 followers

    We knew going into #2025USCHA that there was some *magic* in store for Alchemy at this year’s conference! What transpired over a 4-day span was beyond our expectations, and we are so grateful to have worked with Magic Johnson and NMAC to make this event a huge success for the 3000+ attendees in Washington DC. This year’s theme was “Aging with HIV” and we all knew the best way to commemorate this was by bringing on stage the one and only Earvin “Magic” Johnson. Here are some of the many highlights => 💼 𝗣𝗿𝗶𝘃𝗮𝘁𝗲 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝘄𝗶𝘁𝗵 𝗠𝗮𝗴𝗶𝗰 𝗝𝗼𝗵𝗻𝘀𝗼𝗻 We kicked off an amazing business meeting with Earvin “Magic” Johnson by celebrating the appointment of Harold Phillips as NMAC’s new incoming CEO. We then capped off the morning with a truly unique customer signing event by welcoming AIDS Alabama Inc to the Alchemy portfolio, with Magic helping us mark the occasion. 🤝 𝗠𝗲𝗲𝘁 𝗮𝗻𝗱 𝗚𝗿𝗲𝗲𝘁 𝗘𝘃𝗲𝗻𝘁 𝘄𝗶𝘁𝗵 𝗠𝗮𝗴𝗶𝗰 𝗝𝗼𝗵𝗻𝘀𝗼𝗻 We then transitioned to an intimate Meet and Greet session with select Alchemy and NMAC business partners where everyone had a chance to socialize and take photos with Magic Johnson. There were even some jersey signings and ecstatic fan moments.          🎤 𝗞𝗲𝘆𝗻𝗼𝘁𝗲 𝗖𝗼𝗻𝘃𝗲𝗿𝘀𝗮𝘁𝗶𝗼𝗻 Our Founder & Co-CEO Sid Viswanathan introduced Magic Johnson on stage for a conversation about his life, legacy, and Aging with #HIV. Magic Johnson captivated the audience with a powerful opening keynote sharing his own life experience of being diagnosed and dealing with HIV for over three decades and showing everyone in that room–and beyond what it means to age with HIV gracefully, successfully and with no limitations.  🛠️ 𝗪𝗼𝗿𝗸𝘀𝗵𝗼𝗽𝘀 𝘄𝗶𝘁𝗵 𝗢𝘂𝗿 𝗖𝗹𝗶𝗻𝗶𝗰 𝗣𝗮𝗿𝘁𝗻𝗲𝗿𝘀 Our team and clinic partners helped amplify the Alchemy mission by sharing practical lessons from our work together, including:  • Addressing the Opioid Use Disorder/HIV/Hepatitis C Syndemic Through Mobile Clinics led by our Founder & Co-CEO Peter Park with our partners from Equality Health Group, Raphael Health Center, and The LGBTQ Center.  • Expanding PrEP Access through Pharmacist-Led Initiation led by our Founder & Chief Pharmacist Susie J. Crowe Crowe with partners from Raphael Health Center, The LGBTQ Center, and NASTAD. At Alchemy we are constantly inspired by the amount of compassion and support that exists within the HIV community, but are also reminded of the amount of work that still remains to improve and advance HIV access and equity across the country. We will continue to focus on building in-house pharmacies inside every HIV clinic in the country to further our mission of ensuring America becomes a place where “Aging with HIV” means every person with HIV has high-quality care and treatment, and ages gracefully–free from stigma and discrimination. #2025USCHA #USCHA #AgingwithHIV NMAC

    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
      +3
  • Big congrats to insitro and Eli Lilly and Company on teaming up to build next-gen #machinelearning models for small molecule design! By combining Lilly’s world-class preclinical data with insitro’s ML expertise, this collaboration aims to predict key drug properties (ADMET) faster, cut costly lab work, and accelerate the path to better medicines. Exciting to see this work also extend to partners through Lilly TuneLab. 🔗 https://lnkd.in/eeZ-3Pw4

    View organization page for insitro

    32,890 followers

    We are excited to announce today a new collaboration with Eli Lilly and Company to build next-generation #machinelearning models for small molecule design that save time and reduce experimentation cycles. 💻🧪✨ insitro will build advanced ML models that can accurately predict key pharmacological properties of small molecules, including their behavior in vivo. Our team will train them on Lilly’s robust, proprietary preclinical data, leveraging a rich set of in vitro and in vivo measurements from a vast array of compounds. The models will address a longstanding challenge in drug discovery: how to predict key pharmacological properties of small molecules.  ⚛️🧪 These properties include Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) which have traditionally been slow and costly to determine through experimental methods in the lab. Small molecules that reach the right tissue at the optimal concentration for the right duration result in better patient outcomes. These models:  ✅ will be trained on data from advanced molecules from decades of Lilly’s drug discovery programs, representing a world-class dataset in quality, consistency and scale ✅ will be available to insitro and our partners, Lilly and their partners, including members of Lilly TuneLab, a new platform designed to empower biotechs with cutting-edge #ML tools to transform medicine discovery ✅ could be a game-changer by giving researchers the ability to zero in on drug-like chemical structures at the earliest stages, avoiding significant wasted work and costly failures Read more in the release here: https://lnkd.in/eeZ-3Pw4

  • Health 2.0 Redux: What’s Old is New Again Remember the glory days of the Health 2.0 Conference stage? Our partner Julie Yoo just dropped a must-read Substack on how many of those 2011 startup categories—PHRs included!—are back in action, this time powered by AI. From personal health records to categories that once seemed ahead of their time, it turns out they weren’t “bad ideas,” just “bad timing.” With new tailwinds—AI-native tools, shifting incentives, and unprecedented traction—we believe the timing couldn’t be better for healthcare innovation. Julie’s tl;dr: Pretty much all of the 2011 categories now map to 2025 startup activity. What’s rising from the ashes today feels more viable than ever before. See link below.

    View profile for Julie Yoo

    GP at a16z investing in healthcare; co-founder @kyruushealth

    Health 2.0 Redux: PHRs (Personal Health Records) are so back. What else is back? To answer that question, I revisited the startup categories that made the main stage of the 2011 Health 2.0 Conference (the place to be way before HLTH and ViVE) to see which were featured back then, went dormant, and are now rising like a flock of glorious phoenixes from the ashes, mostly in AI-native form. (2011 was the year my personal fave 2010's era PHR app, the *original* 100plus, raised its seed - h/t Chris Hogg). tl;dr - Pretty much all of the 2011 categories map to 2025-era startup activity. Most, if not all, of these categories are looking more viable now than they did 15 years ago for a variety of reasons. So what’s old is new again, but with a confluence of tailwinds that constitute a much stronger “why now.” All this to say - "There are no bad ideas, just bad timing." It’s never been a better time to build in healthcare - this is the industry that will benefit the most from AI, the space is showing signs of evolution that mirror the patterns of earlier eras of the broader tech industry, and traction levels are unprecedented. Full read and 2011-to-2025 category mappings here: https://lnkd.in/ghP_xZmk cc: Matthew Holt, Eva Steinman, Jane Rhee, Andreessen Horowitz

Affiliated pages

Similar pages